Fresenius Medical Care (NYSE:FMS) Shares Gap Up – Should You Buy?

Fresenius Medical Care AG (NYSE:FMS)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $23.17, but opened at $24.22. Fresenius Medical Care shares last traded at $24.23, with a volume of 53,280 shares traded.

Analyst Ratings Changes

A number of brokerages have weighed in on FMS. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. StockNews.com initiated coverage on shares of Fresenius Medical Care in a report on Friday, January 3rd. They issued a “strong-buy” rating for the company. Berenberg Bank assumed coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price target on the stock. Finally, Truist Financial upped their price objective on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Monday, January 6th.

Fresenius Medical Care Price Performance

The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The stock has a fifty day simple moving average of $22.87 and a two-hundred day simple moving average of $21.00. The company has a market cap of $14.45 billion, a PE ratio of 20.35, a price-to-earnings-growth ratio of 0.75 and a beta of 0.92.

Fresenius Medical Care (NYSE:FMS) last released its earnings results on Tuesday, November 5th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.03. The company had revenue of $5.23 billion during the quarter, compared to the consensus estimate of $5.36 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%. During the same quarter last year, the company earned $0.31 earnings per share. On average, equities analysts predict that Fresenius Medical Care AG will post 1.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care

Several institutional investors and hedge funds have recently made changes to their positions in FMS. Allworth Financial LP grew its position in shares of Fresenius Medical Care by 53.1% in the third quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after purchasing an additional 581 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Fresenius Medical Care during the third quarter worth $38,000. GAMMA Investing LLC raised its holdings in shares of Fresenius Medical Care by 50.4% in the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after acquiring an additional 1,675 shares during the last quarter. ORG Wealth Partners LLC purchased a new stake in shares of Fresenius Medical Care in the third quarter valued at $112,000. Finally, Venturi Wealth Management LLC boosted its stake in shares of Fresenius Medical Care by 1,045.8% during the third quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock valued at $112,000 after acquiring an additional 4,800 shares during the last quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.